Answer
ER-positive, HER2-negative locally advanced or metastatic breast cancer carrying an activating ESR1 mutation after progression on endocrine-based treatment.
Sources for this answer
- Inluriyo 200 mg film-coated tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.